Dr. Humphrey discusses takeaways from NY GU 2022 in RCC/bladder cancer

W. Kimryn Rathmell, MD, PhD, an internationally recognized expert in kidney cancer, is Chair of the Department of Medicine and Physician-in-Chief at Vanderbilt University Medical Center.

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

The novel TKI zanzalintinib demonstrated early efficacy signals with manageable toxicity in patients with advanced clear-cell renal cell carcinoma.

"I think there's a lot of fear that can go into talking about these topics," says Katherine Rotker, MD.

Adjuvant pembrolizumab improved overall survival compared with placebo in patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

The application is based on results from the phase 3 CheckMate-901 trial.